By targeting two clinically relevant immune checkpoints, i.e. LAG-3 and PD-L1, we successfully prevented early-onset tumor development in the preclinical Msh2loxP/loxP mouse model, significantly prolonging overall survival following repetitive low-dose anti-PD-L1 or anti-LAG-3 administration. This evidence concerns the gene LAG3 and neoplasm.